RemeGen's high P/S ratio, driven by current investor sentiment and future expectations, may be concerning given the company's less than stellar revenue forecasts. Unless conditions improve, these prices may not be reasonable.
Despite RemeGen's subdued revenue growth projections, it trades at a P/S ratio similar to the industry, suggesting investors may be less bearish than analysts. However, its weaker revenue outlook could risk a share price decline and pose a risk to shareholders.
$Hang Seng Index (800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN (09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B (02197.HK)$nosedived 9.6% to $0.47, hitting record low.$VIVA BIOTECH (01873.HK)$...
RemeGen Co., Ltd. Stock Forum
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...
The news triggers the sell-off in Hong Kong.
$WUXI BIO (02269.HK)$ $WUXI APPTEC (02359.HK)$ $CLOVER BIO-B (02197.HK)$ $REMEGEN (09995.HK)$
No comment yet